Endometrium
EN-MSC/TERT352-B
Evercyte’s EN-MSC/TERT352-B cell line has been developed from endometrium (endometriosis tissue) -derived mesenchymal stromal cells (MSC). The cells can be grown without limitations, show typical markers and functions of MSCs and therefore represent a valuable model for studying processes such as differentiation, inflammation, tissue homeostasis and repair. In recent years, evidence has accumulated that the potency of mesenchymal stromal cells at least in part is mediated by secreted extracellular vesicles (EVs). EN-MSC/TERT352-B cell line has been established under conditions that will allow the production of EVs for clinical applications.
General information
Cat#: CHT-060-0352-B
Morphology and growth characteristics
EN-MSC/TERT352-B cells can be grown for more than 50 population doublings with a stable growth rate and without showing signs of growth retardation. The cells are characterized by the typical spindle-shaped mesenchymal morphology.
Expression of MSC marker proteins CD73, CD90, CD105
EN-MSC/TERT352-B cells homogenously express typical marker proteins of mesenchymal stromal cells such as CD73, CD90 and CD105, whereas the hematopoietic stem cell marker CD34 is not expressed (green peaks). Cells stained with isotype control antibodies are used as negative control (red peaks).
Biological activity of EN-MSC/TERT352-B derived extracellular vesicles

EN-MSC/TERT352-B cells can be used for the production of extracellular vesicles (EVs). These EVs show the typical EV size and surface marker expression. In addition, EVs derived from EN-MSC/TERT352-B cells show anti- inflammatory and anti-fibrotic activity by significantly reducing NO secretion in a macrophage inflammation assay and α-SMA induction in a TGFß induced fibrosis assay.
FAQs
In vitro propagation
RoosterNourish™-MSC-XF (RoosterBio, Cat# K82016)
RoosterBooster™-MSC-XF (RoosterBio, Cat# SU-016)
RoosterBasal™-MSC2.0-CC (RoosterBio, Cat# M22520)
Additional material & reagents
CellBIND™ tissue culture ware (Corning)
Phosphate buffered saline PBS (Gibco, Cat# 14190-144)
CTS™ TrypLE™ Select Enzyme (Gibco, Cat# A1285901)
Passaging of cells
Remove and discard the culture medium.
Cryopreservation
Freezing medium
CryoStor® cryopreservation medium CS10 (Sigma, Cat# C2874)
Additional material & reagents
Freezing of cells
Detach the cells after having reached about 70-80 % confluence from the culture vessel by using CTS™ TrypLE™ Select Enzyme solution (Protocol passaging of EN-MSC/TERT352-B).
Thawing of cells
Original Evercyte cells are to be thawed in a T25 CellBIND™ tissue culture ware (Corning).
Licence Conditions
The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.
Nonprofit organizations
On time payment for unlimited use: EUR 1700
Profit organizations
Pharmaceutical - chemical- cosmetic industries
Contract research organizations (CRO)
Initial license fee for 3 months: EUR 2700Annual license fee R&D: royalty based
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.